Next Phase Newsletter

A newly established venture fund is currently fundraising for their newest fund and actively pursuing new investment opportunities that they can invest through their new fund. Typical check size is $2-5M, and the firm invests exclusively in therapeutics. The firm focuses on opportunities based in North America, Europe, and Israel. About 20% of their investments to date have been in Europe and Israel, while the rest have been in North America-based companies. 
 
The firm invests exclusively in therapeutics companies, and does not pursue medical devices, diagnostics, or digital health opportunities at this time. Within therapeutics, the firm is most interested in advanced therapeutics including genetic diseases, oncology/immuno-oncology, autoimmune, cardiovascular, ophthalmology, fibrosis, and rare/orphan diseases. The firm is least interested in neurodegenerative, infectious diseases, oligonucleotide, and epigenetic drugs, and does not consider reformulated or repurposed drugs. In terms of stage of development, the firm’s sweet spot is between late pre-clinical stage (after animal data) and Phase II. 
 
The firm seeks to invest in technologies backed by strong IP protection. To date, the firm has mostly led or co-led investment rounds, prefers to take an active stance in their portfolio companies, and requires a board seat. However, the firm is open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A strategic corporate venture fund of a global pharmaceutical company actively invests in early-stage biotech companies that are of strategic interest to the parent pharmaceutical. The firm invests in global opportunities, but focuses primarily on North America and Europe. 
 
The firm invests in early-stage therapeutics and platform technology companies. The firm’s main areas of interest include immunology and inflammation, kidney disease including transplant, serious diseases treated in hospitals, neurodegenerative disease, and rare disease. Regarding platform technologies, the firm is interested in drug discovery technologies for small molecule, peptide, nucleic acid, and other novel modalities, delivery systems (CNS, kidney disease), and cell therapies (excluding those targeting oncology). The firm invests primarily in pre-clinical opportunities, and can consider those as early as discovery stage. The firm does not actively seek opportunities in medical devices, diagnostics, or digital health at this time. 
 
The firm has no specific company or management team requirements. The firm can help support companies beyond capital. The firm can offer scientific expertise, and is able to collaborate on early stage proof-of-concept experiments and projects with emerging companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with offices in Western Europe is currently making investments out of its newest fund that had an initial close recently. The firm looks to make equity investments into early stage companies up to €4M, with a focus on Seed to Series A investment rounds. The firm is actively reviewing new opportunities, with a focus in Europe. About 5-10% of the investments will be made in the US. 
 
With the newest fund, the firm is looking for technologies leveraging AI, digital therapeutics, and digital health platforms (i.e. data aggregation). The firm will consider medical device or diagnostics applications that have a AI component, but is most interested in investing in digital health. The firm is open to investing in companies in the earliest stages of development, pre-pilot. 
 
The firm is looking for privately held companies with experienced management teams. The firm is very open to working with incomplete management teams to help them fill out any gaps in management. The firm looks to be a strong value adding investor providing companies with its access to its network of other investors and strategic partners as well. The firm prefers to act as a lead or co-lead, especially in companies based in Spain, but will prefer to syndicate in opportunities outside of Europe. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An impact-driven venture fund with offices in US and Europe focuses on investments that improve the quality of Life and wellbeing of individuals and for medium and long-term relief of the ever-increasing strain on (public) healthcare, social welfare, and the planet. The firm invests in tech startups using Emerging & Disruptive Technologies (AI, Data, Blockchain, Iot,  AR/VR, and Digital Security) to solve social and environmental challenges within the 4 following SDGs: Health & Wellbeing, Quality Education, Sustainable City and Climate Action. The firm participates in Pre-Seed to Series A rounds with Seed being their sweet spot. The Fund invests across Europe. The firm also has an excellent coaching program to support its portfolio teams. 
 
In terms of Healthcare, the firm is interested in digital health software that helps with disease prevention, optimized recovery and improved quality of life. The firm purely invests in software and is not interested in hardware or devices. 
 
The firm does not have specific company requirements. The firm can act as a (co)lead investor and typically takes a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global integrated business enterprise has a US-based, wholly owned subsidiary that is very interested in expanding the healthcare business and increasing its presence in the US. The firm seeks to make engage with early- and mid-stage healthcare companies through strategic investment, partnerships, and more. The firm is open to global opportunities.  
 
Within life sciences and healthcare sectors, the firm is most interested in medical devices, diagnostics, digital health, and healthcare services. Within medtech, the firm focuses on general surgery, laparoscopic surgery, orthopedics, OB/GYN, urology, GI, ENT, respiratory/anesthesia, radiology, and cardiology. In digital health, technologies addressing areas such as virtual care providers, wellness management, etc. that could benefit the aging population are of interest. The firm is can partner with companies across a wide stage of development, from companies still developing a prototype to those who are already on the market. The firm does not invest in biotech or pharmaceutical companies. 
 
The firm has no specific company or management team requirements. The firm is interested in companies who are looking to enter the Asian market, and can help support the companies in navigating regulatory hurdles by leveraging their own regulatory team. The firm can act as a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture capital firm that was launched within the last year was operating in stealth for the year prior. The firm prefers to invest in Series A, though can also invest in Seed and Series B if there is a great fit. The firm invest in pre-clinical stage and devices already with FDA approval. The firm is a hands-on investor, providing value and leverageable knowledge to the companies from both investor team and the corporation. The firm invests globally with a first ticket of €1-3M. 

 
The firm is largely focused on investing in diagnostics and digital solutions, as well as select life science tools. 
 
The firm prefers to syndicate with other VCs or CVCs, and typically requires a board seat as part of the  hands-on approach to the company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An investment firm founded in 2015 invests in technology, medical, and science-related deals. The firm typically engages in late Seed and Series A financings with typical check size being around $2M. Though the firm’s first searches are in the Midwest US, they are open to all investment opportunities across the US – generally, the firm avoids Boston and Silicon Valley. The firm will lead about half of its investments. 
 
Within life sciences, the firm invests in all sectors but is currently focusing on therapeutics and diagnostics companies. The firm is generally indication-agnostic, but in terms of diagnostics, they are focusing on cancer. For therapeutics companies, the firm prefers them to be about a year before conducting human trials. For medical devices, diagnostics, and digital health, companies should be pre-revenue and pre-FDA approval. 
 
The firm does not require to take a board observer seat but may take one depending on the case. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.